Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H10N2O5 |
Molecular Weight | 190.154 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)N[C@@H](CCC(O)=O)C(O)=O
InChI
InChIKey=LCQLHJZYVOQKHU-VKHMYHEASA-N
InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1
Molecular Formula | C6H10N2O5 |
Molecular Weight | 190.154 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Carglumic acid is a Carbamoyl Phosphate Synthetase 1 (CPS 1) allosteric modulator. CPS1 is found in the mitochondria and is the first enzyme of the urea cycle, which converts ammonia into urea. Carglumic acid acts as a replacement for NAG in NAGS deficiency patients by activating CPS1 but it does not help to regulate the urea cycle. Carglumic acid under the trade name Carbaglu indicated as adjunctive therapy for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). In addition, as maintenance therapy for the treatment of chronic hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). This rare genetic disorder results in elevated blood levels of ammonia, which can eventually cross the blood–brain barrier and cause neurologic problems, cerebral edema, coma, and death.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2362990 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21403788 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CARBAGLU Approved UseCarbaglu (carglumic acid) is a Carbamoyl Phosphate Synthetase 1 (CPS 1) activator indicated as:
• Adjunctive therapy for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). (1.1)
• Maintenance therapy for the treatment of chronic hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). (1.2) Launch Date2010 |
|||
Palliative | CARBAGLU Approved UseCarbaglu (carglumic acid) is a Carbamoyl Phosphate Synthetase 1 (CPS 1) activator indicated as:
• Adjunctive therapy for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). (1.1)
• Maintenance therapy for the treatment of chronic hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). (1.2) Launch Date2010 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2892 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25677217/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARGLUMIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.6 μg/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARGLUMIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25677217/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARGLUMIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25677217/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARGLUMIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.6 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARGLUMIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: (PMDA_A100_2 in Japanese) 23, (PMDA_I100_1 in Japanese) 11-12, 38 |
no | |||
Page: (PMDA_A100_2 in Japanese) 23, (PMDA_I100_1 in Japanese) 12, 39-42 |
no | |||
Page: (PMDA_A100_2 in Japanese) 23, (PMDA_I100_1 in Japanese) 12, 39-42 |
no | |||
Page: (PMDA_A100_2 in Japanese) 23, (PMDA_I100_1 in Japanese) 11-12, 38 |
no | |||
Page: (PMDA_A100_2 in Japanese) 23, (PMDA_I100_1 in Japanese) 12, 39-42 |
no | |||
Page: (PMDA_A100_2 in Japanese) 23, (PMDA_I100_1 in Japanese) 12, 39-42 |
no | |||
Page: (PMDA_A100_2 in Japanese) 23, (PMDA_I100_1 in Japanese) 12, 39-42 |
no | |||
Page: (PMDA_A100_2 in Japanese) 23, (PMDA_I100_1 in Japanese) 12, 39-42 |
no | |||
Page: (PMDA_A100_2 in Japanese) 23, (PMDA_I100_1 in Japanese) 12, 39-42 |
no | |||
Page: (PMDA_A100_2 in Japanese) 23, (PMDA_I100_1 in Japanese) 12, 39-42 |
no | |||
Page: (PMDA_A100_2 in Japanese) 23, (PMDA_I100_1 in Japanese) 11-12, 38 |
no | |||
Page: (PMDA_A100_2 in Japanese) 23, (PMDA_I100_1 in Japanese) 12, 39-42 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 30, 35 |
no | |||
Page: 30.0 |
no | |||
Page: 30.0 |
no | |||
Page: 30.0 |
no |
PubMed
Title | Date | PubMed |
---|---|---|
[Orphan drugs and metabolic disorders]. | 2001 Aug 1-15 |
|
Hyperinsulinism and hyperammonemia syndrome: report of twelve unrelated patients. | 2001 Sep |
|
N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy. | 2002 Dec |
|
N-carbamylglutamate enhances ammonia detoxification in a patient with decompensated methylmalonic aciduria. | 2003 Aug |
|
Hyperammonaemia as a cause of psychosis in an adolescent. | 2003 Nov |
|
Mammalian N-acetylglutamate synthase. | 2004 Apr |
|
Carglumic acid: new preparation. An advance in rare urea cycle disorders. | 2004 Feb |
|
Urea synthesis by ruminal epithelial and duodenal mucosal cells from growing sheep. | 2004 Jun |
|
Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N-carbamylglutamate. | 2004 Oct |
|
N-carbamylglutamate protects patients with decompensated propionic aciduria from hyperammonaemia. | 2005 |
|
Misleading diagnosis of partial N-acetylglutamate synthase deficiency based on enzyme measurement corrected by mutation analysis. | 2005 Jan |
|
Mutations and polymorphisms in the human N-acetylglutamate synthase (NAGS) gene. | 2007 Aug |
|
Carglumic acid: a second look. Confirmed progress in a rare urea cycle disorder. | 2008 Apr |
|
N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. | 2008 Aug |
|
Carglumic acid: an additional therapy in the treatment of organic acidurias with hyperammonemia? | 2008 Jan 30 |
|
[A newborn infant with hyperventilation]. | 2008 Jun 26 |
|
N-acetylglutamate synthase: structure, function and defects. | 2010 |
|
N-carbamylglutamate in emergency management of hyperammonemia in neonatal acute onset propionic and methylmalonic aciduria. | 2010 |
|
Outpatient treatment of propionic acidemia-associated hyperammonemia with N-carbamoyl-L-glutamate in an infant. | 2010 Apr |
|
Dietary supplementation with L-arginine or N-carbamylglutamate enhances intestinal growth and heat shock protein-70 expression in weanling pigs fed a corn- and soybean meal-based diet. | 2010 Aug |
|
Gateways to clinical trials. | 2010 Dec |
|
Carglumic acid approved to treat genetic hyperammonemia. | 2010 May 1 |
Sample Use Guides
Adult Dosage: The recommended initial dose for acute hyperammonemia is 100 mg/kg/day to 250 mg/kg/day. Concomitant administration of other ammonia lowering therapies is recommended. Dosing should be titrated based on individual patient plasma ammonia levels and clinical symptoms.
The recommended maintenance dose should be titrated to target normal plasma ammonia level for age. Based on limited data in 22 patients receiving maintenance treatment with Carbaglu in a retrospective case series, maintenance doses were usually less than 100 mg/kg/day. The total daily dose should be divided into 2 to 4 doses and rounded to the nearest 100 mg. (i.e. half a Carbaglu Tablet)
Pediatric Dosage: The recommended initial dose for acute hyperammonemia is 100 mg/kg/day to 250 mg/kg/day. Concomitant administration of other ammonia lowering therapies is recommended. Dosing should be titrated based on individual patient plasma ammonia levels and clinical symptoms. The recommended maintenance dose should be titrated to target normal plasma ammonia level for age. Based on limited data in 22 patients receiving maintenance treatment with Carbaglu in a retrospective case series, maintenance doses were usually less than 100 mg/kg/day. The total daily dose should be divided into 2 to 4 doses.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26885446
Carglumic acid-treated (1, 5, 10 mM) and untreated cancer cells were stained with propidium iodide to determine DNA contents in the human pancreatic adenocarcinoma cell lines, AsPC1 and human triple-negative breast cancer cell lines MDA-MB-231. The results showed that carglumic acid did not induce complete cell cycle arrest. Instead, we observed more sub-G1 cells among carglumic acid-treated AsPC1 and MDA-MB-231 cells than among untreated cells, indicating that cell death occurred in response to carglumic acid. Sub-G1 cells accounted for 1.6% and 26.3% of untreated and treated AsPC1 cells, respectively , and for 1.8% and 12.8% of untreated and treated MDA-MB-231 cells, respectively. In order to further determine whether cancer cells under go cell death through apoptosis after carglumic acid treatment, we measured caspase activity in AsPC1 cells treated with carglumic acid. The results showed that caspase-3 activity increased in a dose-dependent manner. Together, these data suggest that carglumic acid inhibits cancer cell proliferation by inducing apoptosis.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:31:50 GMT 2025
by
admin
on
Mon Mar 31 18:31:50 GMT 2025
|
Record UNII |
5L0HB4V1EW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
CARBAGLU (AUTHORIZED: AMINO ACID METABOLISM, INBORN ERRORS)
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
||
|
FDA ORPHAN DRUG |
109997
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
||
|
WHO-VATC |
QA16AA05
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/00/007
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
||
|
NDF-RT |
N0000184144
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
||
|
WHO-ATC |
A16AA05
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
||
|
NCI_THESAURUS |
C78275
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
||
|
FDA ORPHAN DRUG |
352111
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID7046706
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
m3108
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000089544
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
1096586
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
1188-38-1
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
SUB20051
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
CARGLUMIC ACID
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
5L0HB4V1EW
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
7458
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
760124
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
3068
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
5L0HB4V1EW
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
C76884
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
XX-21
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
8008
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
401713
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | RxNorm | ||
|
121396
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201780
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
N0000184143
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | Carbamoyl Phosphate Synthetase 1 Activators [MoA] | ||
|
71028
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
DB06775
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
PRIMARY | |||
|
SUB13236MIG
Created by
admin on Mon Mar 31 18:31:50 GMT 2025 , Edited by admin on Mon Mar 31 18:31:50 GMT 2025
|
ALTERNATIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> ACTIVATOR | |||
|
EXCRETED UNCHANGED |
Following administration of a single radiolabeled oral dose of 100 mg/kg of body weight up to 60% of the dose was excreted unchanged in the feces.
FECAL
|
||
|
EXCRETED UNCHANGED |
Following administration of a single radiolabeled oral dose of 100 mg/kg of body weight, 9% of the dose was excreted unchanged in the urine.
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||